FI990134A - Pyridatsino-(4,5-beta)-kinoliini-5-oksidijohdannaisia, niiden valmistus ja niiden käyttö glysiiniantagonisteina - Google Patents

Pyridatsino-(4,5-beta)-kinoliini-5-oksidijohdannaisia, niiden valmistus ja niiden käyttö glysiiniantagonisteina Download PDF

Info

Publication number
FI990134A
FI990134A FI990134A FI990134A FI990134A FI 990134 A FI990134 A FI 990134A FI 990134 A FI990134 A FI 990134A FI 990134 A FI990134 A FI 990134A FI 990134 A FI990134 A FI 990134A
Authority
FI
Finland
Prior art keywords
pyridazino
quinoline
beta
preparation
oxide derivatives
Prior art date
Application number
FI990134A
Other languages
English (en)
Swedish (sv)
Other versions
FI112946B (fi
FI990134A0 (fi
Inventor
Wojciech Danysz
Markus Gold
Ivars Kalvinsh
Christopher Graham Rap Parsons
Irene Piskunova
Eugene Rozhkov
Original Assignee
Mertz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mertz & Co Gmbh & Co filed Critical Mertz & Co Gmbh & Co
Publication of FI990134A0 publication Critical patent/FI990134A0/fi
Publication of FI990134A publication Critical patent/FI990134A/fi
Application granted granted Critical
Publication of FI112946B publication Critical patent/FI112946B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI990134A 1996-07-25 1999-01-25 4-hydroksi-1-okso-1,2-dihydro-pyridatsino-[4,5-b]-kinoliini-5-oksidijohdannaiset, niiden valmistus ja niiden käyttö glysiiniantagonisteina FI112946B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68634696 1996-07-25
US08/686,346 US5776935A (en) 1996-07-25 1996-07-25 Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
PCT/EP1997/004057 WO1998004556A1 (en) 1996-07-25 1997-07-25 Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists
EP9704057 1997-07-25

Publications (3)

Publication Number Publication Date
FI990134A0 FI990134A0 (fi) 1999-01-25
FI990134A true FI990134A (fi) 1999-03-24
FI112946B FI112946B (fi) 2004-02-13

Family

ID=24755940

Family Applications (1)

Application Number Title Priority Date Filing Date
FI990134A FI112946B (fi) 1996-07-25 1999-01-25 4-hydroksi-1-okso-1,2-dihydro-pyridatsino-[4,5-b]-kinoliini-5-oksidijohdannaiset, niiden valmistus ja niiden käyttö glysiiniantagonisteina

Country Status (31)

Country Link
US (1) US5776935A (fi)
EP (1) EP0931081B1 (fi)
JP (1) JP3595342B2 (fi)
KR (1) KR100598206B1 (fi)
CN (1) CN1093860C (fi)
AR (1) AR004158A1 (fi)
AT (1) ATE224894T1 (fi)
AU (1) AU719993B2 (fi)
BR (1) BR9710569A (fi)
CA (1) CA2261923C (fi)
CZ (1) CZ289293B6 (fi)
DE (1) DE69715893T2 (fi)
DK (1) DK0931081T3 (fi)
EA (1) EA001711B1 (fi)
ES (1) ES2180041T3 (fi)
FI (1) FI112946B (fi)
GE (1) GEP20022801B (fi)
HK (1) HK1020193A1 (fi)
HU (1) HU223780B1 (fi)
IL (1) IL128225A (fi)
LT (1) LT4591B (fi)
LV (1) LV12260B (fi)
NO (1) NO310820B1 (fi)
PL (1) PL189572B1 (fi)
PT (1) PT931081E (fi)
SI (1) SI9720048B (fi)
SK (1) SK283536B6 (fi)
TW (1) TW402605B (fi)
UA (1) UA63911C2 (fi)
WO (1) WO1998004556A1 (fi)
ZA (1) ZA976612B (fi)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
CA2457011C (en) * 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7029707B2 (en) * 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7001620B2 (en) 2001-10-03 2006-02-21 Herbal Science, Llc Kavalactone product
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
CN1917892A (zh) * 2003-10-24 2007-02-21 草本制药科学有限责任公司 包含冬青的方法和组合物
US7294353B2 (en) * 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
CA2604078C (en) * 2005-04-08 2013-07-23 Abbott Laboratories Enteric pharmaceutical formulations of choline salt of fenofibric acid
NZ584098A (en) * 2007-09-20 2012-05-25 Cortex Pharma Inc 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
EP2264035A1 (en) * 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP7305560B2 (ja) 2017-06-12 2023-07-10 グリテック， エルエルシー Ｎｍｄａアンタゴニスト及びｄ２／５ｈｔ２ａ又は選択的５ｈｔ２ａアンタゴニストによるうつ病の治療
USD895157S1 (en) 2018-03-06 2020-09-01 IsoTruss Indsutries LLC Longitudinal beam
CN109912503B (zh) * 2019-04-01 2022-04-08 江南大学 一种2,3-二酰基喹啉类化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore

Also Published As

Publication number Publication date
AU4296997A (en) 1998-02-20
EP0931081B1 (en) 2002-09-25
IL128225A (en) 2005-09-25
PT931081E (pt) 2003-02-28
HUP9903104A3 (en) 2000-04-28
CA2261923A1 (en) 1998-02-05
LV12260A (lv) 1999-04-20
WO1998004556A1 (en) 1998-02-05
FI112946B (fi) 2004-02-13
DE69715893D1 (de) 2002-10-31
DK0931081T3 (da) 2003-01-27
CN1228778A (zh) 1999-09-15
CA2261923C (en) 2006-01-24
HUP9903104A2 (hu) 2000-03-28
BR9710569A (pt) 1999-08-17
EA199900161A1 (ru) 1999-10-28
IL128225A0 (en) 1999-11-30
ES2180041T3 (es) 2003-02-01
NO310820B1 (no) 2001-09-03
CZ2019997A3 (cs) 1999-09-15
JP2000515872A (ja) 2000-11-28
SK10399A3 (en) 2000-01-18
LT4591B (lt) 1999-12-27
CZ289293B6 (cs) 2001-12-12
US5776935A (en) 1998-07-07
TW402605B (en) 2000-08-21
CN1093860C (zh) 2002-11-06
AR004158A1 (es) 1998-11-04
PL331323A1 (en) 1999-07-05
ZA976612B (en) 1998-02-10
NO990306D0 (no) 1999-01-22
UA63911C2 (uk) 2004-02-16
LV12260B (en) 1999-08-20
SK283536B6 (sk) 2003-09-11
KR20000029568A (ko) 2000-05-25
ATE224894T1 (de) 2002-10-15
NO990306L (no) 1999-03-15
EP0931081A1 (en) 1999-07-28
DE69715893T2 (de) 2003-01-30
AU719993B2 (en) 2000-05-18
KR100598206B1 (ko) 2006-07-07
JP3595342B2 (ja) 2004-12-02
PL189572B1 (pl) 2005-08-31
HU223780B1 (hu) 2005-01-28
LT99007A (en) 1999-07-26
FI990134A0 (fi) 1999-01-25
SI9720048A (sl) 1999-12-31
SI9720048B (sl) 2002-02-28
EA001711B1 (ru) 2001-06-25
GEP20022801B (en) 2002-09-25
HK1020193A1 (en) 2000-03-31

Similar Documents

Publication Publication Date Title
FI990134A (fi) Pyridatsino-(4,5-beta)-kinoliini-5-oksidijohdannaisia, niiden valmistus ja niiden käyttö glysiiniantagonisteina
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE04617B1 (et) 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena
EE9900147A (et) Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena
EE03680B1 (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
EE03591B1 (et) Dispergeeritavad makromolekulikompositsioonid ja nende valmistamise ning kasutamise meetodid
NZ314184A (en) Substituted quinazoline derivatives and pharmaceutical compositions
EE9700074A (et) Antineoplastilised kakaoekstraktid, meetodid nende valmistamiseks ja nende ksutamine
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
IL129089A0 (en) New derivatives from piperidine-keto acid their preparation and use
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
ZA973097B (en) Novel aspire-hydroxy acid derivatives their preparation and use
HUP9904032A3 (en) 1,2,4-benzothiadiazine derivatives,their preparation and use
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE9900034A (et) Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
FI941914A (fi) 2-amino-4-kinoliinidihydropyridiinejä, menetelmiä niiden valmistamiseksi ja niiden käyttö
BR9612413A (pt) Composto uso do mesmo e composição farmacêutica
ITMI941112A0 (it) Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono
FI961977A (fi) N-substituoidut atsabisykloalkaanijohdannaiset, niiden valmistus ja käyttö
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
EE200000207A (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, nende valmistamine ja terapeutiline kasutamine
FI971317A (fi) Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
EE9900092A (et) PTX-tundlikud G-valgud, nende valmistamine ja kasutamine
AU2152497A (en) Heterocyclic compounds and their preparation and use